The US Food and Drug Administration (FDA) has received reports of serious skin reactions and systemic symptoms, including deaths, among patients taking telaprevir in combination with peginterferon alfa and ribavirin.
The label for telaprevir already warns about the potential for serious skin reactions such as Stevens-Johnson syndrome and drug rash with eosinophilia and systemic symptoms (DRESS). But the FDA has now received 2 reports from Japan of toxic epidermal necrolysis in patients taking telaprevir combination therapy. One of the patients died after therapy was continued despite signs of a skin reaction. The FDA has also received a report of a woman who had developed DRESS and died after telaprevir combination treatment was continued.
Kuehn BM. Telaprevir Warning. JAMA. 2013;309(4):333. doi:10.1001/jama.2013.22
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: